Using lidocaine to lower propofol dosage during gastroscopy
Does Intravenous Lidocaine Reduce ED 50 for Propofol Administered Using Target Controlled Infusion (TCI) During Gastroscopy in ASA 1 and 2 Patients.
This study is testing if giving lidocaine before sedation can help reduce the amount of propofol needed for healthy patients during gastroscopy procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Erasme University Hospital Academic / other |
| Locations | 1 site (Bruxelles) |
| Trial ID | NCT06143410 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate whether intravenous lidocaine can reduce the effective dose (ED50) of propofol when administered via Target Controlled Infusion (TCI) during gastroscopy procedures. Healthy patients classified as ASA 1 and 2 will be randomly assigned to receive either lidocaine or a placebo before sedation with propofol. The study will measure the required dosage of propofol to achieve sedation, comparing the two groups to determine the efficacy of lidocaine in reducing propofol requirements.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults scheduled for gastroscopy with an ASA score of 1 or 2 and a BMI between 18 and 30 kg/m2.
Not a fit: Patients with a history of lidocaine allergy, severe central nervous system disorders, or those who have recently undergone anesthesia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer and more efficient sedation protocols during gastroscopy, minimizing the amount of propofol needed.
How similar studies have performed: While the use of lidocaine in sedation protocols has been explored, this specific approach of reducing propofol dosage during gastroscopy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled for gastroscopy under narcosis and who have signed the consent. * ASA score: 1 and 2 * BMI between 18 and 30 kg/m2 Exclusion Criteria: * Lidocaine allergy * Anesthesia within the last 7 days * Use of local anesthesia in the last 24 hours * Rhythm disorder or HR \<50 * Pregnant women and breastfeeding * Participation in another clinical study in the last months * Cannot understand VAS score or French * Severe central nervous disease and mental illness. * Obstructive sleep apnea (known or STOP BANG score \>5) * Upper lung infection. * Liver or kidney function disorder
Where this trial is running
Bruxelles
- Boudart Céline — Bruxelles, Belgium (Recruiting)
Study contacts
- Principal investigator: Céline Boudart, PhD — Erasme hospital
- Study coordinator: Céline Boudart, PhD
- Email: celine.boudart@hubruxelles.be
- Phone: +322555391+9
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.